The clinical spectrum of Caspr2 antibody–associated disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To report a large cohort of patients with antibodies against contactin-associated protein-like 2 (Caspr2) and provide the clinical spectrum of this disorder.
Methods: Serum and CSF samples were assessed at 2 neuroimmunology centers in Barcelona and Rotterdam. Patients were included if Caspr2 antibodies were confirmed with 2 independent techniques, including brain immunohistochemistry and cell-based assay. Clinical information was obtained by the authors or provided by treating physicians after patients' informed consent.
Results: Median age at symptom onset was 66 years. Of 38 patients, 34 were male. Median time to nadir of disease was 4 months (in 30% >1 year). The most frequent syndromes included limbic encephalitis (42%) and Morvan syndrome (29%). Seventy-seven percent of the patients had ≥3 of the following symptoms: encephalopathy (cognitive deficits/seizures), cerebellar dysfunction, peripheral nervous system hyperexcitability, dysautonomia, insomnia, neuropathic pain, or weight loss. A tumor, mostly thymoma, occurred in 19% of the patients. Immunoglobulin G4 subclass antibodies were present in all patients; 63% also had immunoglobulin G1 antibodies. Treatment response occurred in 93% of the patients and 25% had clinical relapses.
Conclusions: Caspr2 antibodies associate with a treatable disorder that predominantly affects elderly men. The resulting syndrome may vary among patients but it usually includes a set of well-established symptoms. Recognition of this spectrum of symptoms and consideration of the protracted clinical course are important for early diagnosis of this disorder. Prompt immunotherapy and tumor therapy (if needed) often result in improvement.
GLOSSARY
- Caspr2=
- contactin-associated protein-like 2;
- CBA=
- cell-based assay;
- FLAIR=
- fluid-attenuated inversion recovery;
- IgG=
- immunoglobulin G;
- IHC=
- immunohistochemistry;
- IVIg=
- IV immunoglobulin;
- LE=
- limbic encephalitis;
- LGI1=
- leucine-rich glioma-inactivated 1;
- MG=
- myasthenia gravis;
- NMDAR=
- NMDA receptor;
- PNH=
- peripheral nerve hyperexcitability;
- RIA=
- radioimmunoassay;
- VGKC=
- voltage-gated potassium channel
Footnotes
↵* These authors contributed equally to this work.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received December 4, 2015.
- Accepted in final form April 25, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author response: Morvan syndrome and severe hyponatremia
- Agnes van Sonderen, Neurologist, Erasmus University Medical Center, Rotterdam, the Netherlandsm.titulaer@erasmusmc.nl
- Helena Arino, Josep Dalmau, Maarten J Titulaer
Submitted September 13, 2016 - Morvan syndrome and severe hyponatremia
- Han Chen, Physician, Department of Neurology, Third Xiangya Hospital, Central South University, Chang Sha, Chinahchen_xy3yy@sina.com
Submitted August 24, 2016
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Farwa Ali and Dr. Lauren Jackson
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Views and Reviews
Encephalitis and antibodies to synaptic and neuronal cell surface proteinsEric Lancaster, Eugenia Martinez-Hernandez, Josep Dalmau et al.Neurology, July 11, 2011 -
Article
Thymoma and Autoimmune EncephalitisClinical Manifestations and AntibodiesMar Guasp, Jon Landa, Eugenia Martinez-Hernandez et al.Neurology: Neuroimmunology & Neuroinflammation, July 23, 2021 -
Article
Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravisEstefanía Torres-Vega, Nuria Mancheño, Arantxa Cebrián-Silla et al.Neurology, March 01, 2017 -
Article
Anti-LGI1 encephalitisClinical syndrome and long-term follow-upAgnes van Sonderen, Roland D. Thijs, Elias C. Coenders et al.Neurology, September 02, 2016